• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型无环大麻素-1受体反向激动剂N-[(1S,2S)-3-(4-氯苯基)-2-(3-氰基苯基)-1-甲基丙基]-2-甲基-2-{[5-(三氟甲基)吡啶-2-基]氧基}丙酰胺(tarabanat,MK-0364)的构象分析及受体对接

Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.

作者信息

Lin Linus S, Ha Sookhee, Ball Richard G, Tsou Nancy N, Castonguay Laurie A, Doss George A, Fong Tung M, Shen Chun-Pyn, Xiao Jing Chen, Goulet Mark T, Hagmann William K

机构信息

Departments of Medicinal Chemistry, Molecular Systems, Process Research, and Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07065, USA.

出版信息

J Med Chem. 2008 Apr 10;51(7):2108-14. doi: 10.1021/jm7014974. Epub 2008 Mar 12.

DOI:10.1021/jm7014974
PMID:18333607
Abstract

X-ray crystallographic, NMR spectroscopic, and computational studies of taranabant afforded similar low-energy conformers with a significant degree of rigidity along the C11-N13-C14-C16-C17 backbone but with more flexibility around bonds C8-C11 and C8-O7. Mutagenesis and docking studies suggested that taranabant and rimonabant shared the same general binding area of CB1R but with significant differences in detailed interactions. Similar to rimonabant, taranabant interacted with a cluster of aromatic residues (F(3.36)200, W(5.43)279, W(6.48)356, and Y(5.39)275) through the two phenyl rings and with F(2.57)170 and L(7.42)387 through the CF 3-Pyr ring. The notable distinction between taranabant and rimonabant was that taranabant was hydrogen-bonded with S(7.39)383 but not with K(3.28)192, while rimonabant was hydrogen-bonded with K(3.28)192 but not with S(7.39)383. The strong hydrogen bonding between the amide NH of taranabant and hydroxyl of S(7.39)383 was key to the superior affinity of taranabant to CB1R.

摘要

对taranabant的X射线晶体学、核磁共振光谱学和计算研究表明,其具有相似的低能量构象异构体,沿C11-N13-C14-C16-C17主链具有显著的刚性,但在C8-C11和C8-O7键周围具有更大的灵活性。诱变和对接研究表明,taranabant和利莫那班共享CB1R相同的一般结合区域,但在详细相互作用方面存在显著差异。与利莫那班类似,taranabant通过两个苯环与一组芳香族残基(F(3.36)200、W(5.43)279、W(6.48)356和Y(5.39)275)相互作用,并通过CF 3-吡啶环与F(2.57)170和L(7.42)387相互作用。taranabant和利莫那班之间的显著区别在于,taranabant与S(7.39)383形成氢键,但不与K(3.28)192形成氢键,而利莫那班与K(3.28)192形成氢键,但不与S(7.39)383形成氢键。taranabant的酰胺NH与S(7.39)383的羟基之间的强氢键是taranabant对CB1R具有卓越亲和力的关键。

相似文献

1
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.新型无环大麻素-1受体反向激动剂N-[(1S,2S)-3-(4-氯苯基)-2-(3-氰基苯基)-1-甲基丙基]-2-甲基-2-{[5-(三氟甲基)吡啶-2-基]氧基}丙酰胺(tarabanat,MK-0364)的构象分析及受体对接
J Med Chem. 2008 Apr 10;51(7):2108-14. doi: 10.1021/jm7014974. Epub 2008 Mar 12.
2
Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.新型大麻素-1受体反向激动剂N-[(1S,2S)-3-(4-氯苯基)-2-(3-氰基苯基)-1-甲基丙基]-2-甲基-2-[[5-(三氟甲基)吡啶-2-基]氧基]丙酰胺(MK-0364)在啮齿动物中的抗肥胖功效。
J Pharmacol Exp Ther. 2007 Jun;321(3):1013-22. doi: 10.1124/jpet.106.118737. Epub 2007 Feb 27.
3
Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.N-[(1S,2S)-3-(4-氯苯基)-2-(3-氰基苯基)-1-甲基丙基]-2-甲基-2-氨基丙酰胺作为人大麻素-1受体(CB1R)反向激动剂的合成与评价
Bioorg Med Chem Lett. 2009 Sep 1;19(17):5195-9. doi: 10.1016/j.bmcl.2009.07.046. Epub 2009 Jul 24.
4
Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant.塔兰宾构象限制类似物的合成及大麻素受体结合亲和力。
Bioorg Med Chem Lett. 2010 Aug 15;20(16):4757-61. doi: 10.1016/j.bmcl.2010.06.127. Epub 2010 Jul 1.
5
In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys.新型大麻素-1受体反向激动剂塔那班特在大鼠和猴子体内及体外的代谢
Xenobiotica. 2010 Sep;40(9):650-62. doi: 10.3109/00498254.2010.501117.
6
Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans.大麻素-1反向激动剂[14C]塔那班特在人体中的代谢与排泄
Xenobiotica. 2010 Oct;40(10):691-700. doi: 10.3109/00498254.2010.509820.
7
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.新型无环大麻素-1受体反向激动剂N-[(1S,2S)-3-(4-氯苯基)-2-(3-氰基苯基)-1-甲基丙基]-2-甲基-2-{[5-(三氟甲基)吡啶-2-基]氧基}丙酰胺(MK-0364)用于治疗肥胖症的发现。
J Med Chem. 2006 Dec 28;49(26):7584-7. doi: 10.1021/jm060996+.
8
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.非环状CB1R反向激动剂替拉那班通过增加能量消耗和减少热量摄入来介导体重减轻。
Cell Metab. 2008 Jan;7(1):68-78. doi: 10.1016/j.cmet.2007.11.012.
9
The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.发现了taranabant,一种用于治疗肥胖症的选择性大麻素-1受体反向激动剂。
Arch Pharm (Weinheim). 2008 Jul;341(7):405-11. doi: 10.1002/ardp.200700255.
10
Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.发现 N-[(4R)-6-(4-氯苯基)-7-(2,4-二氯苯基)-2,2-二甲基-3,4-二氢-2H-吡喃[2,3-b]吡啶-4-基]-5-甲基-1H-吡唑-3-甲酰胺(MK-5596)作为一种新型大麻素 1 型受体(CB1R)反向激动剂,用于治疗肥胖症。
J Med Chem. 2010 May 27;53(10):4028-37. doi: 10.1021/jm100023j.

引用本文的文献

1
Efficient microwave-assisted Suzuki-Miyaura cross-coupling reaction of 3-bromo pyrazolo[1,5-]pyrimidin-5(4)-one: towards a new access to 3,5-diarylated 7-(trifluoromethyl)pyrazolo[1,5-]pyrimidine derivatives.3-溴吡唑并[1,5 - ]嘧啶-5(4)-酮的高效微波辅助铃木-宫浦交叉偶联反应:通往3,5 - 二芳基化7-(三氟甲基)吡唑并[1,5 - ]嘧啶衍生物的新途径
RSC Adv. 2021 Jan 4;11(3):1287-1302. doi: 10.1039/d0ra07959f.
2
In Vitro and In Silico Characterization of G-Protein Coupled Receptor (GPCR) Targets of Phlorofucofuroeckol-A and Dieckol.Phlorofucofuroeckol-A 和 Dieckol 作用的 G 蛋白偶联受体 (GPCR) 靶点的体外和计算研究
Mar Drugs. 2021 Jun 4;19(6):326. doi: 10.3390/md19060326.
3
GPR6 Structural Insights: Homology Model Construction and Docking Studies.
GPR6 结构研究进展:同源建模与对接研究。
Molecules. 2020 Feb 7;25(3):725. doi: 10.3390/molecules25030725.
4
Methods for the Development of In Silico GPCR Models.计算机模拟GPCR模型的开发方法。
Methods Enzymol. 2017;593:405-448. doi: 10.1016/bs.mie.2017.05.005. Epub 2017 Jul 14.
5
High-resolution crystal structure of the human CB1 cannabinoid receptor.人类CB1大麻素受体的高分辨率晶体结构。
Nature. 2016 Dec 22;540(7634):602-606. doi: 10.1038/nature20613. Epub 2016 Nov 16.
6
Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.开发诱导线粒体生物合成用于治疗急慢性退行性疾病的疗法。
J Med Chem. 2016 Dec 8;59(23):10411-10434. doi: 10.1021/acs.jmedchem.6b00669. Epub 2016 Sep 27.
7
Structural Basis of Species-Dependent Differential Affinity of 6-Alkoxy-5-Aryl-3-Pyridinecarboxamide Cannabinoid-1 Receptor Antagonists.6-烷氧基-5-芳基-3-吡啶甲酰胺类大麻素-1受体拮抗剂物种依赖性差异亲和力的结构基础
Mol Pharmacol. 2015 Aug;88(2):238-44. doi: 10.1124/mol.115.098541. Epub 2015 May 26.
8
Probing the interaction of SR141716A with the CB1 receptor.探究 SR141716A 与 CB1 受体的相互作用。
J Biol Chem. 2012 Nov 9;287(46):38741-54. doi: 10.1074/jbc.M112.390955. Epub 2012 Sep 20.
9
In silico investigation of interactions between human cannabinoid receptor-1 and its antagonists.计算机模拟研究人类大麻素受体-1 与其拮抗剂的相互作用。
J Mol Model. 2012 Aug;18(8):3831-45. doi: 10.1007/s00894-012-1381-8. Epub 2012 Mar 9.
10
Progress in structure based drug design for G protein-coupled receptors.基于结构的G蛋白偶联受体药物设计进展。
J Med Chem. 2011 Jul 14;54(13):4283-311. doi: 10.1021/jm200371q. Epub 2011 Jun 15.